Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
DNA Quote, Financials, Valuation and Earnings
Last price:
$6.75
Seasonality move
:
-39.96%
Day range:
$9.20 - $9.72
52-week range:
$5.00 - $17.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.94x
P/B ratio:
1.05x
Volume:
979.2K
Avg. volume:
1M
1-year change:
6.59%
Market cap:
$588.3M
Revenue:
$227M
EPS (TTM):
-$6.23
Analysts' Opinion
-
Consensus RatingGinkgo Bioworks Holdings, Inc. has received a consensus rating of No Consensus. The company's average rating is a No Consensus based on 1 Buy rating, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, Ginkgo Bioworks Holdings, Inc. has an estimated upside of 2.99% from its current price of $9.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $9.71.
Fair Value
-
According to the consensus of 2 analysts, Ginkgo Bioworks Holdings, Inc. has 2.99% upside to fair value with a price target of $10.00 per share.
DNA vs. S&P 500
-
Over the past 5 trading days, Ginkgo Bioworks Holdings, Inc. has overperformed the S&P 500 by 0.22% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ginkgo Bioworks Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ginkgo Bioworks Holdings, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ginkgo Bioworks Holdings, Inc. reported revenues of $38.8M.
Earnings Growth
-
Ginkgo Bioworks Holdings, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ginkgo Bioworks Holdings, Inc. reported earnings per share of -$1.45.
Enterprise value:
540.5M
EV / Invested capital:
--
Price / LTM sales:
2.94x
EV / EBIT:
--
EV / Revenue:
2.99x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.89x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$75M
Return On Assets:
-25.83%
Net Income Margin (TTM):
-188%
Return On Equity:
-50.92%
Return On Invested Capital:
-30.68%
Operating Margin:
-227.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $315M | $218M | $180.6M | $89M | $38.8M | |
| Gross Profit | $142.5M | $119.7M | $75M | $59.9M | $11.9M | |
| Operating Income | -$812.3M | -$515.4M | -$344.2M | -$51.6M | -$88.2M | |
| EBITDA | -$697M | -$455.2M | -$283.2M | -$34.5M | -$74M | |
| Diluted EPS | -$17.89 | -$12.90 | -$6.23 | -$1.08 | -$1.45 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.8B | $1.5B | $1.1B | $662.5M | $506.1M | |
| Total Assets | $2.2B | $1.9B | $2B | $1.5B | $1.2B | |
| Current Liabilities | $90.3M | $124.8M | $168.5M | $114.4M | $115.3M | |
| Total Liabilities | $532.6M | $431M | $773.7M | $682.9M | $629.4M | |
| Total Equity | $1.6B | $1.4B | $1.3B | $797.9M | $559.8M | |
| Total Debt | $16.3M | $59.8M | $403.7M | $445.6M | $422.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$342.2M | -$335M | -$165.8M | -$103.5M | -$31.6M | |
| Cash From Investing | -$4.3M | -$95.8M | -$348.5M | -$10.2M | -$72.8M | |
| Cash From Financing | $95.2M | -$2.2M | $9.4M | -$465K | $9.9M | |
| Free Cash Flow | -$405.2M | -$387.3M | -$187.2M | -$118.6M | -$31.6M | |
DNA
Sector
Market Cap
$588.3M
$25.8M
Price % of 52-Week High
55.23%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
-0.49%
-1.64%
1-Year Price Total Return
6.59%
-18.88%
Beta (5-Year)
--
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.21
200-day SMA
Sell
Level
$10.44
Bollinger Bands (100)
Sell
Level
7.96 - 12.3
Chaikin Money Flow
Sell
Level
-61M
20-day SMA
Buy
Level
$9.17
Relative Strength Index (RSI14)
Buy
Level
54.48
ADX Line
Buy
Level
12.73
Williams %R
Neutral
Level
-38.7283
50-day SMA
Buy
Level
$9.11
MACD (12, 26)
Buy
Level
0.00
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-47.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.9551)
Sell
CA Score
(Annual)
Level (-1.3308)
Buy
Beneish M-Score
(Annual)
Level (-3.2566)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.4338)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, DNA has received 1 Buy ratings 0 Hold ratings, and 1 Sell ratings. The DNA average analyst price target in the past 3 months is $10.00.
-
Where Will Ginkgo Bioworks Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ginkgo Bioworks Holdings, Inc. share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Ginkgo Bioworks Holdings, Inc.?
Analysts are divided on their view about Ginkgo Bioworks Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ginkgo Bioworks Holdings, Inc. is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Ginkgo Bioworks Holdings, Inc.'s Price Target?
The price target for Ginkgo Bioworks Holdings, Inc. over the next 1-year time period is forecast to be $10.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ginkgo Bioworks Holdings, Inc. is a No Consensus. 1 of 2 analysts rates the stock a No Consensus at this time.
-
How Can I Buy Shares Of DNA?
You can purchase shares of Ginkgo Bioworks Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ginkgo Bioworks Holdings, Inc. shares.
-
What Is The Ginkgo Bioworks Holdings, Inc. Share Price Today?
Ginkgo Bioworks Holdings, Inc. was last trading at $6.75 per share. This represents the most recent stock quote for Ginkgo Bioworks Holdings, Inc.. Yesterday, Ginkgo Bioworks Holdings, Inc. closed at $9.71 per share.
-
How To Buy Ginkgo Bioworks Holdings, Inc. Stock Online?
In order to purchase Ginkgo Bioworks Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DNA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DNA
Sector
P/E ratio
--
23.44x
PEG ratio
--
-0.01x
P/B ratio
1.05x
1.81x
Price / LTM sales
2.94x
1.56x
Growth Metrics
DNA
Sector
Revenue growth
-56.39%
3.27%
Earnings growth
-34.39%
9.66%
Revenue (5-year growth)
33.18%
6.43%
Earnings forecast
-$1.11
-$0.20
Profitability
DNA
Sector
Profitability FY 2024
$137.5M
$2.3M
Return on invested capital
-30.68%
-33.49%
Return on assets
-25.83%
-29.74%
Return on equity
-50.92%
-39.33%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
Feb
28
Estimated Next Earnings Date
May
30
Balance Sheet
DNA
Sector
Total cash
$470.7M
$24.2M
Short term investments
--
$23.8M
Total assets
$1.4B
$71.1M
Long term debt
$422.9M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
